OSIRIS THERAPEUTICS, INC.
OSIR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for OSIR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2018.
Tracking 4 pipeline candidates for OSIRIS THERAPEUTICS, INC..
Run OSIRIS THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available OSIRIS THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
19.9 months
D/E 0.29
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Frequently asked questions
What is OSIRIS THERAPEUTICS, INC.'s lead drug candidate?
OSIRIS THERAPEUTICS, INC.'s most advanced tracked candidate is cartiform (Approved) for Articular cartilage lesions.
Who is the CEO of OSIRIS THERAPEUTICS, INC.?
Jason Keefer is the chief executive officer of OSIRIS THERAPEUTICS, INC. (OSIR).
What therapeutic areas does OSIRIS THERAPEUTICS, INC. focus on?
OSIRIS THERAPEUTICS, INC. develops therapies across Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.